Pharmaceutical - Jetrea

Filter

Current filters:

Jetrea

Popular Filters

Thrombogenics gets Spanish reimbursement approval for Jetrea

Thrombogenics gets Spanish reimbursement approval for Jetrea

01-09-2014

Ophthalmic specialist ThromboGenics has received reimbursement in Spain from the Spanish Ministry of…

AlconJetreaNon-steroidal anti-inflammatory drugsOphthalmicsPharmaceuticalRegulationSpainThromboGenics

Thrombogenics’ Jetrea gains first Latin American approval in Uruguay

Thrombogenics’ Jetrea gains first Latin American approval in Uruguay

02-07-2014

Belgium-based biopharma firm ThromboGenics has said that Jetrea (ocriplasmin) has been approved in Uruguay…

JetreaOphthalmicsPharmaceuticalRegulationThromboGenicsUruguay

ThromboGenics to begin Jetrea study in USA

ThromboGenics to begin Jetrea study in USA

04-03-2014

Belgium-based biopharma firm ThromboGenics will soon initiate a US Phase IV study with Jetrea (ocriplasmin).

AlconBelgiumJetreaOphthalmicsPharmaceuticalResearchThromboGenics

NICE issues final guidance on Jetrea

NICE issues final guidance on Jetrea

23-10-2013

NICE has published final guidance recommending Jetrea (ocriplasmin) from ThromboGenics.

EuropeJetreaOphthalmicsPharmaceuticalRegulationThromboGenics

UK's NICE recommends ThromboGenics' Jetrea for vitreomacular traction

30-08-2013

The UK's National Institute of Health and Care Excellence (NICE) has published final draft guidance recommending…

EuropeHealthcareJetreaOphthalmicsPharmaceuticalThromboGenics

Germany's IQWiG confirms Jetrea's added value for VMT patients

02-08-2013

Belgian biopharma company ThromboGenics (Euronext Brussels: THR) announced today (August 2) that the…

BiotechnologyEuropeJetreaOphthalmicsPharmaceuticalPricingRegulationThromboGenics

ThromboGenics' Jetrea gets initial NICE recommendation for VMT

12-06-2013

Belgium-based biopharma company ThromboGenics (Euronext Brussels: THR) said this morning (June 12) that…

AlconEuropeJetreaNovartisOphthalmicsPharmaceuticalPricingRegulationThromboGenics

Alcon and ThromboGenics Jetrea launched in Denmark and Sweden

28-05-2013

Belgium's ThromboGenics (Euronext Brussels: THR) says that its partner Alcon, the eye care subsidiary…

AlconEuropeJetreaMarkets & MarketingNovartisOphthalmicsPharmaceuticalThromboGenics

EU approval of Jetrea triggers a 45 million-euro milestone for ThromboGenics from Alcon

18-03-2013

The European Commission has approved Swiss drug major Novartis' (NOVN: VX) Alcon ophthalmic unit's Jetrea…

AlconEuropeFinancialJetreaNovartisOphthalmicsPharmaceuticalRegulationThromboGenics

ThromboGenics starts Jetrea roll-out in USA

15-01-2013

With the launch of its Jetrea (ocriplasmin) in the USA imminent, Belgian drugmaker ThromboGenics (Euronext…

BiotechnologyFinancialJetreaMarkets & MarketingOphthalmicsPharmaceuticalThromboGenics

Fujifilm Diosynth to manufacture ocriplasmin for ThromboGenics

20-11-2012

In a second major deal in less than a month, Japanese firm Fujifilm Diosynth Biotechnologies has added…

BiotechnologyFujifilm Diosynth BiotechnologiesJetreaocriplasminOphthalmicsPharmaceuticalProductionThromboGenics

US FDA approves ThromboGenics' Jetrea; advisory backing for Aegerion's lomitapide

19-10-2012

Belgian drugmaker ThromboGenics NV (Euronext Brussels: THR) yesterday received US Food and Drug Administration…

Aegerion PharmaceuticalsCardio-vascularJetrealomitapideNorth AmericaOphthalmicsPharmaceuticalRegulationThromboGenics

Ph III trials show Novartis' Jetrea improves vitreomacular traction

17-08-2012

Swiss drug major Novartis (NOVN: VX) that the New England Journal of Medicine (NEJM) this week published…

AlconJetreaNovartisocriplasminOphthalmicsPharmaceuticalResearchThromboGenics

Back to top